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epigenetic; chromatin; transcription factor; gene expression EPITHELIAL NA ϩ CHANNEL (ENaC) is expressed in the apical membrane of salt-absorbing epithelia of kidney, distal colon, and lung where it constitutes the rate-limiting step in active Na ϩ and fluid absorption. In the renal collecting duct (CD), ENaC expressed in the apical membrane in concert with the basolateral Na ϩ -K ϩ -ATPase mediates Na ϩ reabsorption, and thereby contributes importantly to the control of extracellular fluid volume and blood pressure (4) . ENaC consists of ␣-, ␤-, and ␥-subunits, which are encoded by the Scnn1a ("␣ENaC" in this report), Scnn1b, and Scnn1c genes. Of these genes, ␣ENaC appears to be critical to overall salt balance, as evidenced by the finding that targeted inactivation of ␣ENaC in the connecting tubule (CNT)/CD of mice results in severe renal salt wasting characteristic of a pseudohypoaldosteronism type I phenotype (6) . Moreover, ␣ENaC also appears to be ratelimiting for aldosterone induction of ENaC activity in the CD, since aldosterone administration or hyperaldosteronism induced by a low-Na ϩ diet increases ␣ENaC gene transcription, without increasing ␤-or ␥-subunit expression or ␣ENaC mRNA turnover (14) .
Although it is known that ENaC functional activity is strictly dependent on the level of ␣ENaC expression in the CD principal cells (14) , only limited information exists regarding the specific mechanisms governing its transcriptional regulation. Under basal conditions, ␣ENaC gene transcription is active, but constrained. It can be induced by aldosterone and other stimuli, including the immediate early gene Sgk1 and the circadian regulatory protein casein kinase (CK)1␦/ε (8), even in the absence of steroids (7) . While it has long been known that aldosterone stimulates ␣ENaC transcription in CD cells (14) and that part of this response is mediated through the action of aldosterone, liganded to the mineralocorticoid receptor (MR), acting at a glucocorticoid-responsive element (GRE) at Ϫ811 of the ␣ENaC gene (11), MR-independent effects have also been described. Notably, mice with CNT/CD-specific knockout of the MR did not develop the severe saltwasting phenotype (19) observed with ␣ENaC knockout in these same segments (6) . Indeed, we discovered epigenetic repression/derepression pathways in mouse inner medullary collecting duct (mIMCD)3 cells controlling a major component of basal and aldosterone-sensitive ␣ENaC gene transcription, which involves combinatorial interactions of histone methyltransferase Dot1a with either Sirt1 (26) or Af9 (27) (28) (29) . Af9 binds ϩ78/ϩ92 in the R3 subregion (Ϫ57/ϩ438) of the ␣ENaC promoter and recruits Dot1a to this position to basally repress promoter ␣ENaC transcription in mIMCD3 cells (30) . Aldosterone relieves this repression by dispersing the Dot1a-Af9 complex from the ␣ENaC promoter, prompting histone H3 Lys79 hypomethylation, thereby favoring a chromatin configuration that induces ␣ENaC transcription (27) (28) (29) . As proof of principle, mice with CNT/CD-specific targeted inactivation of Dot1a were found to exhibit greater ␣ENaC mRNA levels compared with controls (30) .
Despite the basal constraints of Dot1a-Af9 on the ␣ENaC promoter, basal ␣ENaC transcription is nonetheless evident and, indeed, functionally necessary for physiologic control of salt and body fluid volume balance. Thus, positive regulatory elements that drive basal transcription of the ␣ENaC gene in CD principal cells must exist. The proximal ␣ENaC gene control region lacks TATA and CAAT boxes, but does contain GC-rich sequences proximal to the transcription start site that could serve as binding sites for Specificity protein (Sp)-1, a member of the Sp/Krüppel-like factor (KLF) transcription factors (Sp/KLF factors hereafter). Accordingly, the present study was designed to examine three questions. First, what factor(s) drives, albeit in a constrained manner, ␣ENaC transcription to meet normal ion transport demands in the CD? Second, how does this basal "driver" integrate with the Dot1a-Af9 basal repression mechanism? Third, does this basal driver contribute to aldosterone induction of the ␣ENaC gene? We discovered that Sp1 binding to a ϩ222/ϩ229 cis-element of the ␣ENaC promoter contributes significantly as a basal driver of ␣ENaC, acting independently from and overcoming the Dot1a-Af9 repressor complex. In addition, aldosterone further enhances Sp1 occupancy of the ␣ENaC promoter; this is required for full induction of promoter activity and is blocked by the MR antagonist spironolactone.
MATERIALS AND METHODS
Reagents and plasmids. Aldosterone was from Sigma (St. Louis, MO). The SYBR GreenER qPCR SuperMix Universal and Lipofectamine 2000 reagent were purchased from Invitrogen (Carlsbad, CA). The LightShift Chemiluminescent EMSA kit was form Pierce (Rockford, IL). Several plasmids have been previously described (27) (28) (29) : pGL3-basic-1.3ENaC␣ contains the murine ␣ENaC promoter fused to the gene-encoding firefly luciferase; pcDNA3.1-Zeo-1.3ENaC␣-Luc contains the 1.3-kb ENaC␣ promoter and luciferasecoding cassette from pGL3-basic-1.3ENaC␣ subcloned into pcDNA3.1-Zeo; pcDNA3.1-Zeo-1.3ENaC␣
⌬Af9ϩ78/ϩ92 -Luc harbors point mutations in the Af9 element between ϩ78 and ϩ92; pFLAGAf9 and pEGFP-Dot1a are expression plasmids encoding epitopetagged Af9 and Dot1a. A new construct, pcDNA3.1-Zeo-1.3ENaC␣-Luc (WT) or pcDNA3.1-Zeo-1.3ENaC␣
⌬Sp1ϩ222/ϩ229 -Luc (⌬ϩ222/ ϩ229), which contains point mutations in the Sp1 element between ϩ222 and ϩ229 ( Fig. 1) , was generated by the Quick Change Site-directed Mutagenesis Kit (Stratagene, Santa Clara, CA), according to the manufacturer's protocols. DNA-sequencing analysis verified all mutations. The Sp1 expression plasmid pBS-Sp1 was from Addgene (Cambridge, MA). Antibodies directed against Sp1 (07-645, Millipore), Sp3 (07-107, Millipore), Af9 (70R-8261, Fitzgerald), Dot1L (EB06356, Everest Biotech), and P84/THOC1 (sc-136426, Santa Cruz Biotechnology) were purchased from commercial vendors. mIMCD3 cell culture, aldosterone treatment, transient and stable transfections, and luciferase assays. Culture of mIMCD3 cells, aldosterone treatment, transient and stable transfections, and luciferase assays of promoter activity were performed as described (28, 29) . mIMCD3 cells were cultured at 37°C in a 5% CO 2 environment in DMEM/F-12 plus 10% fetal bovine serum. For aldosterone treatment experiments, the cells were cultured in medium of the same composition, except containing 10% charcoal-stripped fetal bovine serum for at least 24 h, before 1 nM or 1 M aldosterone or 0.01% ethanol was added as vehicle control. Throughout the text, except as indicated, 1 M aldosterone was used. Cell lines stably transfected with pcDNA3.1-Zeo-1.3ENaC␣-Luc and pcDNA3.1-Zeo-1.3␣ENaC ⌬Af9ϩ78/ϩ92 -Luc (30) have been characterized. Additional stable cell lines were generated by transfecting mIMCD3 cells with pcDNA3.1-Zeo-1.3␣ENaC ⌬Sp1ϩ222/ϩ229 -Luc, followed by clonal selection under Zeocin treatment. Promoter activities were assayed using the Dual-Luciferase Reporter Assay System (Promega, Madison, WI) and were normalized to cell protein content. siRNA knockdown was performed using the Lipofectamine 2000 reagent (Life Technologies, Grand Island, NY) and control (sc-37007, Santa Cruz Biotechnology) and Sp1-specific (sc-29488, Santa Cruz Biotechnology) siRNAs by methods previously described (30) .
EMSA and antibody competition assays. A double-strand Sp1 oligomer corresponding to nucleotides ϩ208 to ϩ240 of the ␣ENaC promoter (wild-type: 5=-GTCAGCTGGGCCAAGAGGGCGTGAA-AGCCGGAGA-3=; mutation: 5=-GTCAGCTGGGCCAAtctttatgGA-AAGCCGGAGA-3=) was 3= end-labeled with biotin using the Biotin 3= End DNA labeling kit (Pierce). For antibody competition assays, 0.2-2.0 g of rabbit polyclonal antibodies against Sp1, Sp3, or nonimmune IgG were used. After being transferred to nylon membranes, biotin-labeled DNA was detected by using LightShift Chemiluminescent EMSA kit (Pierce) according to the manufacturer's instructions.
Chromatin immunoprecipitation/qPCR, re-chromatin immunoprecipitation/qPCR, and RT-qPCR. Chromatin immunoprecipitation (ChIP)/ qPCR and re-ChIP/qPCR were performed and analyzed essentially as previously described (27, 29) using the ChiP-IT Express Enzymatic Kit and Re-ChIP-IT kit (Active Motif), except that antibodies directed against Sp1, Af9, and Dot1a were used and only the R3 subregion (Ϫ57 to ϩ438) of the ␣ENaC promoter was examined. Briefly, mIMCD3 cells were fixed with formaldehyde, harvested, and chromatin was enzymatically sheared according to the manufacturer's protocol. Chromatin immune precipitates were isolated on protein G magnetic beads using 2 g of Sp1, Af9, or Dot1a antibodies or 2 g IgG. These antibody amounts were determined to be optimal in pilot titration experiments. After being washed, the chromatin immune precipitates were eluted, reverse cross-linked, and subjected to agarose gel analysis and qPCR. For re-ChIP, chromatin immune precipitates from the first ChIP were desalted over columns, incubated with the protein G magnetic beads and second antibody or IgG, and processed as above. ChIPs were normalized to input DNA and the IgG control. RT-qPCR to measure ␣ENaC and GAPDH mRNA levels in mIMCD3 cells utilized methods and primers as previously described (16) .
Immunoblots. Cytoplasmic and nuclear extracts from mIMCD3 cells were prepared using the Nuclear/Cytosol Fractionation Kit (BioVision) according to the manufacturer's manual. Samples (40 g) of nuclear and cytoplasmic protein extracts were resolved by SDS-PAGE, and the proteins were electrophoretically transferred to polyvinylidene difluoride membranes (Hybond ECL; Amersham). The blots were probed with antibodies against Sp1 or P84/THOC1 (as a housekeeping nuclear protein) at 0.2 g/ml overnight at 4°C. The blots were washed extensively with a solution containing 50 mM Tris, pH 8.0, 138 mM NaCl, 2.7 mM KCl, and 0.05% Tween 20. The antigen-antibody complexes were detected by the enhanced chemiluminescence protocol using horseradish peroxidase-conjugated donkey anti-rabbit IgG or anti-mouse IgG as secondary antibody.
Data analysis. Quantitative data are expressed as means Ϯ SE and were analyzed for statistical significance by one-way ANOVA or Student's t-test as appropriate. P values Ͻ0.05 were taken as significant. 
RESULTS
Sp1 binds to the ␣ENaC ϩ222/ϩ229 element. Analysis of the murine ␣ENaC promoter region using the Transcription Element Search System (http://www.cbil.upenn.edu/tess) revealed that ϩ222/ϩ229 conforms to an Sp1 consensus sequence as in Fig. 1 . We previously demonstrated that Sp1 is basally expressed in mIMCD3 cells (25) . To determine whether endogenous Sp1 binds to the ϩ222/ϩ229 cis-element of ␣ENaC, EMSAs with mIMCD3 cell nuclear extracts and a wild-type oligomer corresponding to ϩ208/ϩ240 or a mutant ϩ208/ϩ240 oligomer, in which ϩ222/ϩ229 was mutated ( Fig.  1 ), were performed. As seen in Fig. 2A , three DNA-protein complexes were formed using mIMCD3 nuclear extracts with the ϩ208/ϩ240 oligomer. The abundance of complex A was consistently abrogated by addition of a 40-fold molar excess of unlabeled wild-type ϩ208/ϩ240 oligomer but not by the mutant ϩ208/ϩ240 oligomer ( Fig. 2A) , indicating that complex A represents a ϩ222/ϩ229-specific DNA-protein complex. The two lower migrating, nonspecific complexes were not altered by unlabeled wild-type oligomer. In antibody interference assays, antibody against Sp1 almost completely eliminated complex A, with no appreciable changes in the abundance of the other complexes (Fig. 2B ). Nonimmune IgG (as a control) and antibody against Sp3 were without effect on any of the DNA-protein complexes (Fig. 2B) . These results are consistent with an effect of anti-Sp1 antibody to disrupt the DNA-protein complex A. Collectively, these EMSA and antibody interference data indicate that endogenous Sp1 is involved primarily in the formation of the specific DNA-protein complex A. Since complex A was not entirely abolished, it is possible that additional proteins contribute in a minor way to this DNA-protein complex.
To establish the importance of the ϩ222/ϩ229 site to Sp1 binding in the context of chromatin, mIMCD3 cell lines stably expressing pcDNA3.1-Zeocin-1.3ENaC␣-Luc ("WT") or pcDNA3.1-Zeo-1.3ENaC␣
") were established and subjected to ChIP/qPCR with anti-Sp1 antibody (or IgG as a negative control) and primers designed to amplify the R3 subregion of the ␣ENaC promoter. As seen in Fig.  2C , the ⌬Sp1 ϩ222/ϩ229 promoter exhibited greatly reduced enrichment of Sp1 compared with the WT promoter. The fact that some residual Sp1 binding was retained despite the ⌬Sp1 ϩ222/ϩ229 mutation suggests that another Sp1 sequence may reside in the rest of the 1.3-kb gene control region included in the promoter reporter construct.
ϩ222/ϩ229 Sp1 element positively regulates basal and aldosterone-stimulated ␣ENaC promoter activity. To determine the functional relevance of the ϩ222/ϩ229 Sp1 element, we tested the basal luciferase activity of the WT and ⌬Sp1 ϩ222/ϩ229 mIMCD3 cell lines (as used in Fig. 2C ). The results (Fig. 3 ) revealed robust activity of the WT promoter, whereas the activity for the ⌬Sp1 ϩ222/ϩ229 promoter was ϳ40% lower ( B: antibody interference assays were performed using 2 g of nonimmune IgG or rabbit polyclonal antibodies against Sp1 or Sp3 (as a specificity control). Sp1 antibody decreased formation of complex A, whereas Sp3 antibody had no effect. Gel is representative of 4 experiments. C: mutations of the ϩ222/ϩ229 site as in Fig. 1 were introduced into pcDNA3.1-Zeo-1.3ENaC␣-Luc to create pcDNA3.1-Zeo-1.3ENaC␣ ⌬Sp1ϩ222/ϩ229 -Luc as described under MATE-RIALS AND METHODS. Stable mIMCD3 cell lines harboring the pcDNA3.1-Zeo-1.3ENaC␣-Luc (WT) or pcDNA3.1-Zeo-1.3ENaC␣ ⌬Sp1ϩ222/ϩ229 -Luc (⌬ϩ222/ϩ229) constructs were established. Chromatin immunoprecipitation (ChIP)/ qPCR experiments with anti-Sp1 antibody and primers to amplify the R3 subregion were conducted. The value for the final amplicon/input DNA obtained from the WT cells was set as 1, and that of the ⌬ϩ222/ϩ229 was normalized to it. Error bars indicate Ϯ SE. *P Ͻ 0.05 vs. WT; n ϭ 3.
3), indicating the functional importance of the mutated element in basal ␣ENaC promoter function. To determine directly whether Sp1 trans-activates the ␣ENaC promoter via binding to the ϩ222/ϩ229 site, the WT and ⌬Sp1 ϩ222/ϩ229 cell lines were transiently transfected with an Sp1 expression ("pBSSp1") plasmid or its empty parental vector and then treated with vehicle or aldosterone. The total amounts of DNA transfected were held constant. We previously demonstrated that this protocol reproducibly increases Sp1 expression by sixfold in mIMCD3 cells (Fig. 2B in Ref. 25) . As shown in the histogram of reporter gene activity in Fig. 4A , Sp1 overexpression trans-activated basal and aldosterone-stimulated activities of the WT promoter-reporter by 42 and 34%, respectively, but not those of the ⌬Sp1 ϩ222/ϩ229 promoter-reporter. Since endogenous Sp1 is basally expressed at high levels in mIMCD3 cells (25) , these Sp1 overexpression experiments may not represent the full impact of Sp1 on basal ␣ENaC transcription. Accordingly, we used RNA interference to test the impact of endogenous Sp1 depletion on the basal activity of pcDNA3.1-Zeocin-1.3ENaC␣-Luc ("WT") and of pcDNA3.1-Zeo-1.3ENaC␣
"). We previously showed that this siRNA protocol results in a 70% reduction in Sp1 nuclear protein compared with mIMCD3 cells transfected with an equimolar amount of negative control siRNA (Fig. 3A in Ref. 25) . Consistent with our hypothesis that Sp1 trans-activates the WT promoter via the ϩ222/ϩ229 element, basal and aldosterone-stimulated pcDNA3.1-Zeocin-1.3ENaC␣-Luc activities were 59 and 53% lower, respectively, in the cells transfected with Sp1 siRNA compared with the control-transfected cells (Fig. 4B) . In contrast, Sp1 silencing did not significantly affect the activity of the pcDNA3.1-Zeo-1.3ENaC␣ ⌬Sp1ϩ222/ϩ229 -Luc construct under basal or aldosterone-treated conditions (Fig. 4B) , consistent with the fact that the ChIP/qPCR results showed dramatic impairment of Sp1 binding to this promoter template (Fig. 2C) . In agreement with the promoter activity data, cells transfected with Sp1 siRNA also exhibited basal and aldosterone-stimulated endogenous ␣ENaC mRNA levels that were 50 and 30% lower, respectively, than cells transfected with negative control siRNA (Fig. 5) .
Sp1 regulation of ␣ENaC is independent of that mediated by Dot1a/Af9. Since one potential explanation for the stimulatory effects of Sp1 on basal ␣ENaC transcription might be that Sp1 antagonizes binding of Af9 to the R3 subregion of the ␣ENaC promoter, we performed sequential ChIP experiments with antibodies to Af9 or Sp1 (or IgG as a negative control) and ) cell lines were transiently transfected with control siRNA or Sp1-specific siRNA. After 24 h, the cells were treated with vehicle or aldosterone for 24 h, and then the firefly activities were measured and normalized to cell protein content. The value obtained for control siRNA-transfected cells harboring pcDNA3.1-Zeo-1.3ENaC␣-Luc (WT) was set to 1, and the other conditions were normalized to it. The values shown are the mean of triplicate determinations of 3 independent experiments. Error bars indicate Ϯ SE. *P Ͻ 0.05 vs. vehicletreated, control siRNA-transfected. **P Ͻ 0.05 vs. aldosterone-treated, control siRNA-transfected. ␣ENaC primers targeting the R3 subregion to determine whether they co-occupy the promoter in mIMCD3 cells. The chromatin immunoprecipitates with the Af9 antibody were reimmunoprecipitated with antibodies specific for Sp1 or IgG.
Reciprocal sequential ChIP/qPCR (Sp1 ChIP followed by Af9 or IgG re-ChIP) was also performed. Agarose gel analysis of the ChIP and re-ChIP samples produced with the antibodies yielded the expected PCR product, whereas the IgG samples exhibited negligible signal (Fig. 6A ). qPCR analysis of reverse cross-linked DNAs from the second round of immunoprecipitates, normalized to background IgG, confirmed enrichment of Af9 or Sp1 in the re-ChIP samples (Fig. 6B) . The quantitative differences between the two reciprocal sequential ChIPs (Fig.  6B ) likely represent differences in the stability of the Af9 vs. Sp1 antibodies with chromatin throughout the procedure. Collectively, these results indicate that Sp1 and Af9 co-occupy the R3 subregion of the ␣ENaC promoter. We next tested whether Af9 can bind to the ϩ222/ϩ229 Sp1 element. Immunopurified FLAG-Af9 (30) was used in EMSA with the ϩ208/ϩ240 oligomers as in Fig. 2A . Despite exhaustive attempts using a variety of binding conditions, we could not detect a sequence-specific gel shift with FLAG-Af9 (n ϭ 5, not shown). Similarly, we tested whether Sp1 might bind to the neighboring ϩ78/ϩ92 Af9 element by determining whether the Sp1 antibody could supershift or inhibit the Af9-DNA complex using the Af9 oligomer ϩ74/ϩ107 we previously used (30) . There was no change in the migration or abundance of the Af9-DNA protein complexes (n ϭ 3, not shown). We conclude that an interaction of Af9 with the ϩ222/ϩ229 Sp1 site or of Sp1 with the ϩ78/ϩ92 Af9 element does not occur under these conditions. We then questioned whether Sp1 might partner with Af9 through protein-protein interactions. We performed coimmunoprecipitation experiments in which immunoprecipitation of mIMCD3 nuclear extracts with anti-Sp1 antibody was followed by immunoblotting with anti-Af9 antibody. Reciprocal coimmunoprecipitations were performed (n ϭ 3). We also performed GST pull-down experiments with GST-Af9 to capture Sp1 from mIMCD3 cell lysates (n ϭ 4, not shown). With either method, no definitive evidence of Sp1-Af9 proteinprotein interaction was observed.
We also performed ChIP/qPCR assays using the mIMCD3 cell lines stably expressing the wild-type and Sp1 ϩ222/ϩ229 mutant promoter-reporter constructs to determine whether impaired Sp1 binding to the mutant promoter affects Af9 or Dot1a enrichment in chromatin associated with the R3 subregion. As seen in Fig. 7, A and B, no significant differences in Af9 or Dot1 occupancy, respectively, were observed between the wild-type and Sp1 ϩ222/ϩ229 mutant templates. Consistent with these ChIP/qPCR results, the activity of stably expressed pcDNA3.1-Zeo-1.3ENaC␣ ⌬Sp1ϩ222/ϩ229 -Luc was comparable in cells transiently transfected with pEGFP-mDot1a or empty vector-transfected cells (Fig. 7C) . We previously demonstrated that pEGFP-mDot1a transfection reproducibly yields Dot1a protein overexpression in mIMCD3 cells (Fig. 6 in Ref. 27) . Moreover, the activity of the Af9 ϩ78/ϩ92 binding site mutant pcDNA3.1-Zeo-1.3ENaC␣ ⌬Af9ϩ78/ϩ92 -Luc was virtually identical in cells transfected with empty vector or the Sp1 expression plasmid pBS-Sp1 (Fig. 7D) . The collective results indicate that Sp1 and Af9 bind and function independently through their respective cis-elements in the ␣ENaC R3 subregion and that the effects of Sp1 are functionally independent of those exerted by the Dot1a/Af9 complex.
Aldosterone promotes Sp1 occupancy of the ␣ENaC promoter. Whereas the pcDNA3.1-Zeo-1.3ENaC␣ ⌬Sp1ϩ222/ϩ229 -Luc construct exhibited a fold-increase in aldosterone-stimulated promoter activity in the Sp1 trans-activation and knockdown experiments that was comparable with the WT promoterreporter construct, the absolute magnitude of induction of the mutated construct was significantly less than that of the WT construct (Fig. 4, A and B) . Accordingly, we tested whether aldosterone (1 nM or 1 M) induced additional Sp1 occupation of the ␣ENaC promoter beyond basal levels. We performed ChIP/qPCR analysis of Sp1 occupancy at the ␣ENaC R3 subregion following vehicle or aldosterone treatment of mIMCD3 cells for 2 h. We selected this time point because in previous ChIP/qPCR time course studies, we demonstrated that aldosterone triggered RNA pol II occupancy (together with significant decreases in both Af9 occupancy and associated Dot1a-mediated histone H3 trimethylated K79) beginning at 2 h of aldosterone treatment in mIMCD3 cells (30) . Consistent with the fact that the GRE resides outside R3, we also did not observe MR occupancy of the ␣ENaC R3 subregion in those studies (30) . As seen in Fig. 8A, 1 M (but not 1 nM) aldosterone treatment resulted in a significant increase in Sp1 occupation of the R3 subregion at 2 h, an effect that was blocked by the MR antagonist spironolactone. Immunoblots of nuclear extracts showed no significant differences in Sp1 nuclear abundance between vehicle-and 1-M aldosterone-treated mIMCD3 cells (Fig. 8B) , indicating that the additional recruitment of Sp1 occurred from a nascent pool of Sp1 protein.
DISCUSSION
An integrated genetic-epigenetic model of ␣ENaC gene regulation requires knowledge of the action of constitutive and inducible transcription factors, constitutive and inducible chromatin-modifying enzymes, and their interplay. Our analysis of the ␣ENaC 5=-flanking region previously revealed that the R3 subregion (Fig. 1) is the major site for aldosterone-sensitive and MR-independent epigenetic control of ␣ENaC transcription by Dot1a in mIMCD3 cells and contains a functional Af9 The cells were transfected with control siRNA or Sp1-specific siRNA. After 24 h, the cells were treated with vehicle or aldosterone for 24 h, and then total RNA was harvested, and ␣ENaC and GAPDH mRNA levels were measured by qRT-PCR. The normalized ENaC␣/GAPDH mRNA levels are presented. *P Ͻ 0.05 vs. vehicle-treated, control siRNA-transfected. **P Ͻ 0.05 vs. aldosterone-treated, control siRNA-transfected; n ϭ 3.
cis-element at ϩ78/ϩ92 that nucleates this effect. In this study, we build on this earlier work by demonstrating in mIMCD3 cells that Sp1 is required as a basal trans-activator of the ␣ENaC gene by binding to an Sp1 element at ϩ222/ϩ229 of the ␣ENaC proximal promoter. Several lines of evidence suggest that the action of Sp1 at ϩ222/ϩ229 is independent of the repressive effects of the neighboring Dot1a-Af9 complex: 1) Sp1 and Af9 did not interact in coimmunoprecipitation assays or GST pull-down assays (not shown); 2) FLAG-Af9 did not bind the ϩ222/ϩ229 element in gel shift assays (not shown); 3) mutation of the Sp1 element at ϩ222/ϩ229 did not alter Af9 (Fig. 7A) or Dot1a (Fig. 7B ) occupancy at the R3 subregion compared with the wild-type ␣ENaC promoter; 4) Dot1a overexpression did not alter the activity of the Sp1 ϩ222/ϩ229 mutant ␣ENaC promoter (Fig. 7C) ; and 5) Sp1 overexpression did not alter the activity of the Af9 ϩ78/ϩ92 mutant ␣ENaC promoter (Fig. 7D) . Finally, we discovered, unexpectedly, that aldosterone triggers further increases in Sp1 occupation of the R3 subregion of the ␣ENaC promoter (Fig.  8A ) without increasing nuclear levels of Sp1 (Fig. 8B) and that this response is blocked by the MR antagonist spironolactone (Fig. 8A) and is required to achieve the maximal magnitude of ␣ENaC transcriptional induction (Fig. 4, A and B) .
The effect of Sp1 on the ␣ENaC promoter in mIMCD3 cells was likely direct and mediated principally by DNA binding, since mutation of the ϩ222/ϩ229 element disrupted the Sp1 DNA-binding activity in vitro ( Fig. 2A) and in the context of chromatin in intact cells (Fig. 2C) , impaired basal ␣ENaC promoter activity when introduced into the promoter-reporter plasmid (Fig. 3) , abrogated Sp1-mediated trans-activation of the ␣ENaC promoter in overexpression experiments (Fig. 4A) , and rendered the ␣ENaC promoter completely unresponsive to the inhibitory effects of Sp1 siRNA (Fig. 4B) . The binding of Sp1 to this region was specific since the formation of the complex A was inhibited by the addition of an excess of unlabeled sequence, but not by an excess of unlabeled sequence in which the ϩ222/ϩ229 element was mutated (Fig.  2A) . The fact that Sp1 antibody did not completely abolish complex A suggests that other proteins may contribute to a small degree to the complex. We do not believe that Af9, Sp3, or Sp4 are present in the complex, since we did not detect an effect of Af9 or Sp3 antibodies to alter the abundance or mobility of complex A, and we previously demonstrated that Sp4 is not expressed in mIMCD3 cells (25) .
In addition to the liganded MR (11), another inducible stimulus of ␣ENaC transcription-the circadian clock protein ChIP with Sp1 or IgG, followed by re-ChIP with Af9 or IgG, was also performed. Precipitated R3 subregion segments were detected using agarose gels (A: representative of 3 independent experiments) and quantified by qPCR (B: n ϭ 3). Relative chromatin enrichment was calculated as described in MATERIALS AND METHODS.
Period 1 (Per1)-has been described. Mice with global knockout of the circadian clock protein Per1 exhibit ␣ENaC levels in the inner medulla and increased urinary sodium excretion compared with wild-type control mice (10) . siRNA knockdown of Per1 resulted in lower levels of ␣ENaC mRNA in mIMCD3 cells (10) . Although transient cotransfection of Per1 with a human ␣ENaC promoter-luciferase construct in these mIMCD3 cells did enhance the basal ␣ENaC promoter activity (10), other evidence suggests that the effects of Per1 are triggered by inducible circadian regulatory networks. For example, in a qualitative assay of nascent transcription, no effect of Per1 knockdown on the basal expression of endogenous ␣ENaC hnRNA was evident in two of three replicates in mIMCD3 cells (Fig. 6A in Ref. 10) , although an effect was evident in the mpkCCDC 14 cell line (9) . Further studies in the mpkCCDC 14 cell line revealed that 1) under basal conditions, Per1 binds only weakly to each of four E-boxes in the ␣ENaC promoter under basal conditions in DNA affinity precipitation assays (9) and 2) the effect of Per1 to enhance ␣ENaC mRNA levels was dependent on the action of the circadian regulatory protein CK1␦/ε (8) to trigger Per1 nuclear entry and Per1 interaction with the circadian protein Clock (9, 17) . Thus, while Per1 may contribute to the known circadian variation in ␣ENaC gene expression (10) , it apparently does not account for the large component of basal ␣ENaC transcription that is not subject to circadian control (10) but required for basal salt and body fluid volume homeostasis. Rigorous studies controlling for circadian influences to analyze any potential interaction of Per1 with the basal transcriptional machinery of ␣ENaC in CD cells will be required.
In previous work, we demonstrated that the MR blocker spironolactone only partially inhibited aldosterone induction of ␣ENaC promoter activity (26), suggesting MR-dependent and -independent effects of aldosterone on ␣ENaC transcription in ⌬Sp1ϩ222/ϩ229 -Luc (⌬Sp1 ϩ222/ϩ229 ) was immunoprecipitated with the Af9 antibody or IgG. Precipitated R3 subregion segments were quantified by qPCR (n ϭ 3). The value for Af9-IP amplicon/input DNA obtained from pcDNA3.1-Zeo-1.3ENaC␣-Luc (WT) was set to 1, and the value from pcDNA3.1-Zeo-1.3ENaC␣
⌬Sp1ϩ222/ϩ229 -Luc (⌬Sp1 ϩ222/ϩ229 ) was normalized to it. The values shown are the mean of triplicate determinations of 3 independent experiments. Error bars indicate Ϯ SE. No statistically significant differences between group means were detected. B: chromatin from mIMCD3 cells stably transfected with pcDNA3.1-Zeo-1.3ENaC␣-Luc (WT) or the Sp1 binding site mutant pcDNA3.1-Zeo-1.3ENaC␣
⌬Sp1ϩ222/ϩ229 -Luc (⌬Sp1 ϩ222/ϩ229 ) was immunoprecipitated with the Dot1a antibody or IgG. Precipitated R3 subregion segments were quantified by qPCR (n ϭ 3). The value for Dot1a-IP amplicon/input DNA obtained from pcDNA3.1-Zeo-1.3ENaC␣-Luc (WT) was set to 1, and the value from pcDNA3.1-Zeo-1.3ENaC␣
⌬Sp1ϩ222/ϩ229 -Luc (⌬Sp1 ϩ222/ϩ229 ) was normalized to it. The values shown are the mean of triplicate determinations of 3 independent experiments. Error bars indicate Ϯ SE. No statistically significant differences between group means were detected. C: mIMCD3 cells stably transfected with pcDNA3.1-Zeo-1.3ENaC␣-Luc (WT) or the Sp1 binding site mutant pcDNA3.1-Zeo-1.3ENaC␣
⌬Sp1ϩ222/ϩ229 -Luc (⌬Sp1 ϩ222/ϩ229 ) were transiently transfected with a EGFP-mDot1a expression vector or EGFP vector. After 24 h, the firefly activities were measured and normalized to cell protein content. The value obtained for EGFP-transfected cells was set to 1, and that of the pEGFP-mDOt1a-transfected cells was normalized to it. The values shown are the mean of triplicate determinations of 3 independent experiments. Error bars indicate Ϯ SE. No statistically significant differences between group means were detected. D: mIMCD3 cells stably transfected with pcDNA3.1-Zeo-1.3ENaC␣-Luc (WT) or the Af9 binding site mutant pcDNA3.1-Zeo-1.3ENaC␣ ⌬Af9ϩ78/ϩ92 were transiently transfected with empty vector or the Sp1 expression vector pBS-Sp1. After 24 h, the firefly activities were measured and normalized to cell protein content. The value obtained for vector-transfected cells was set to 1, and that of the pBS-Sp1-transfected cells was normalized to it. The values shown are the mean of triplicate determinations of 3 independent experiments. Error bars indicate Ϯ SE. No statistically significant differences between group means were detected. mIMCD3 cells, and consistent with findings that mice with CNT/CD-specific knockout of the MR exhibited reduced, but still evident, ␣ENaC expression compared with wild-type mice (19) . In the present study, we found that spironolactone completely abolished the aldosterone induction of Sp1 binding to the ␣ENaC (Fig. 8) , suggesting that this aldosterone-induced Sp1 occupancy is MR-dependent. We did not observe this effect with 1 nM aldosterone, indicating that this may be relevant only in states of aldosterone excess. Since the known GRE at Ϫ811 to which the liganded MR binds (11) is remote from the Sp1 site, and no MR occupancy is evident in the R3 subregion of the ␣ENaC promoter in aldosterone-treated mIMCD3 cells (30) , DNA-looping in chromatin may be responsible for the MR dependence of the Sp1 effect in aldosterone induction of ␣ENaC transcription. Precise regulation of gene transcription often requires such interactions between spatially remote cis-acting regulatory sequences with the looping out of the intervening DNA. Further studies with chromosome conformation capture and ChIP-loop methods will be required to test this hypothesis.
It is now clear that aldosterone induces ␣ENaC transcription by orchestrating a complex series of transcriptional events that includes both classical trans-activation and epigenetic derepression mechanisms. Aldosterone trans-activation of ␣ENaC is mediated principally by the action of the liganded MR binding to a GRE at Ϫ811 of the ␣ENaC promoter, but also includes the actions of Per1 binding to an E-box at Ϫ689 (17, 20) and MR-dependent Sp1 binding to its cognate element as described in the present report. The epigenetic mechanism, which we previously characterized, involves dispersal of a Dot1a-Af9 from the ϩ78/ϩ92 Af9 element of the ␣ENaC promoter, Sgk1-dependent phosphorylation of Af9 with disruption of the Dot1a-Af9 complex (29) , and consequent histone H3K79 hypomethylation (30) . These aldosterone-dependent trans-activation and epigenetic derepression mechanisms appear to be coincident based on time course experiments, but independent. For example, in contrast to the ability of aldosterone to downregulate expression levels of Dot1a (27), Af9 (27) , and Sirt1 (26) in mIMCD3 cells to make these repressors less abundant and available to the ␣ENaC promoter, aldosterone upregulates Per1 expression in CD cells (10), but does not affect the expression level of Sp1 in mIMCD3 cells (Fig. 7) , instead triggering Sp1 recruitment to the ␣ENaC promoter. Moreover, while Sp1 has been shown to trans-activate the Sgk promoter in some experimental conditions (1), and phosphorylation regulates Sp1 trafficking (24), Sgk1 is not known to phosphorylate and regulate Sp1.
Sp1 regulates the expression of numerous genes that have GC-rich, typically TATA-less promoters (24) , including ␣ENaC. In such TATA-less and/or GC-rich promoters, Sp1 binds its target DNA sequence via three tandem zinc finger motifs in its COOH terminus and may nucleate recruitment of other transcription factors or cofactors, such as TATA-binding proteinassociated factors, which then engage other components of the transcriptional machinery such as transcription factor IID to initiate transcription (15) . Despite its ubiquitous expression, numerous studies, including those of Sp1 knockout mice (24) , indicate that Sp1 often functions in a cell type-, stimulus-, and gene-specific manner. Various cell-specific binding partners, chromatin modifiers, and signaling events dictate this specificity. For example, Sp1 trans-activates the genes encoding filtrin (18) and podocalyxin (5) specifically in podocytes. Sp1 is critically involved in epithelial-mesenchymal transition transcriptional networks (22) , control of circadian clock genes (13) , and tops the list of promoter-enhancer modules involved in differentiation of human stem cells (12) . As other examples, Sp1 is part of the TNF-␣ enhanceosome (21) , controls a variety of estrogen-inducible genes (23) , and the glucocorticoid responsiveness of the AT1b receptor gene (2) . Additionally, posttranslational modifications, such as phosphorylation, glycosylation, ubiquitinylation, acetylation, ribosylation, and SUMOylation, affect Sp1 regulation of target genes in various cell types (3) . Whether specific posttranslational modifications account for the aldosterone-induced recruitment of additional, nascent Sp1 to ϩ222/ϩ229 of ␣ENaC in mIMCD3 cells (Fig.  8A) remains open for investigation, but since this Sp1 recruit- ment occurred in the absence of detectable changes nuclear Sp1 protein abundance (Fig. 8B) , a posttranslational signaling event seems plausible. Given that the major regulators of basal (Dot1a, Af9, and Sp1), and circadian (Per1) ␣ENaC transcription are also expressed in cell types in which ␣ENaC is not expressed, discovery and characterization of the cell-specific determinants for ␣ENaC transcription in CD principal cells are very important. Further studies are required to address this question.
The present results do not address the effects of Sp1 on ENaC activity, the key physiologic response. Despite our efforts with collaborators who are experts in ENaC channel activity measurements, we have been frustrated in our attempts to reproducibly and directly measure ENaC activity in mIMCD3 cells subjected to experimental manipulation of transfections (for overexpression or knockdown of regulatory components) and culturing in charcoal-stripped serum for aldosterone induction: the results have been highly variable owing to the fragility of the cells. Thus, we could not test whether Sp1 overexpression or knockdown altered ENaC activity. We do know, however, that the ϳ50% reduction in basal ␣ENaC mRNA levels that we observed with Sp1 knockdown in this report (Fig. 5 ) is equivalent to that achieved with Dot1a overexpression in mIMCD3 cells (Fig. 4A in Ref. 16 ). The Dot1a-overexpressing mIMCD3 cells exhibited benzamil-sensitive intracellular Na ϩ concentrations (as an index of ENaCmediated Na ϩ transport and as measured by changes in the signal of the intracellular fluorescence of sodium-binding benzofuran isophthalate-acetoxymethyl ester in single-cell fluorescence imaging) that were less than half of vector-transfected controls (Fig. 8E in Ref. 16) . Thus, to the extent that equivalent ␣ENaC mRNA levels can be extrapolated to ENaC activity, the Sp1 effects observed here are likely to be physiologically relevant.
In summary, we demonstrated that Sp1 binding to ϩ222/ ϩ229 of ␣ENaC independently offsets Dot1a-Af9-mediated epigenetic repression to foster basal ␣ENaC transcription in CD cells. Moreover, aldosterone-mediated, MR-dependent enrichment of Sp1 at this element is required for maximal aldosterone induction of the gene. These results should enable a better understanding of how the balance of these opposing functions is altered during other states of altered ␣ENaC transcription and in other epithelia.
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